BLACK DIAMOND THERAPEUTICS, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2025-11-06
- BLACK DIAMOND THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2025-09-30 was 0.00 shares.
- BLACK DIAMOND THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2024-09-30 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month |
|---|---|---|
| 2025-09-30 | 0.00 shares 10-Q · filed 2025-11-06 | 10.76K shares 10-Q · filed 2025-11-06 |
| 2024-09-30 | 0.00 shares 10-Q · filed 2025-11-06 | 0.00 shares 10-Q · filed 2025-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |